keyword
MENU ▼
Read by QxMD icon Read
search

abobotulinumtoxinA

keyword
https://www.readbyqxmd.com/read/28657917/patient-registry-of-spasticity-care-world-data-analysis-based-on-physician-experience
#1
Alberto Esquenazi, Stella Lee, Nathaniel Mayer, Roser Garreta, Atul Patel, Elie Elovic, Stephen Koelbel, Gerard Francisco, Iris Reuter
OBJECTIVE: The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. DESIGN: A prospective, multicenter, international observational registry design was used. RESULTS: Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians...
June 28, 2017: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/28654586/botulinum-toxin-for-neck-rejuvenation-assessing-efficacy-and-redefining-patient-selection
#2
Samer F Jabbour, Elio G Kechichian, Cyril J Awaida, Roland R Tomb, Marwan W Nasr
BACKGROUND: The "Nefertiti lift" consists of injecting the platysmal bands and the inferior border of the mandible with botulinum toxin. No clinical trial has evaluated its effect on the different lower face and neck aging components, and little is known about the clinical characteristics that predict treatment success. METHODS: Patients were injected with abobotulinumtoxinA along the inferior border of the mandible and into the platysmal bands. Using standardized preinjection and postinjection photographs, the jowls, marionette lines, oral commissures, neck volume, and platysmal bands at maximal contraction and at rest were assessed with validated photonumeric scales...
July 2017: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28639368/botulinum-toxin-state-of-the-art
#3
REVIEW
Joseph Jankovic
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions...
June 22, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28634000/dose-dependent-effects-of-abobotulinumtoxina-dysport-on-spasticity-and-active-movements-in-adults-with-upper-limb-spasticity-secondary-analysis-of-a-phase-3-study
#4
Michael W O'Dell, Allison Brashear, Robert Jech, Thierry Lejeune, Philippe Marque, Djamel Bensmail, Ziyad Ayyoub, David M Simpson, Magali Volteau, Claire Vilain, Philippe Picaut, Jean Michel Gracies
BACKGROUND: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. OBJECTIVE: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. DESIGN: Secondary analysis of a phase 3 study (NCT01313299). SETTING: Multicenter, international, double-blind, placebo-controlled clinical trial...
June 19, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28625615/efficacy-and-safety-of-abobotulinumtoxina-dysport-for-the-treatment-of-hemiparesis-in-adults-with-upper-limb-spasticity-previously-treated-with-botulinum-toxin-subanalysis-from-a-phase-3-randomized-controlled-trial
#5
Christina Marciniak, Peter McAllister, Heather Walker, Allison Brashear, Steven Edgley, Thierry Deltombe, Svetlana Khatkova, Marta Banach, Fatma Gul, Claire Vilain, Philippe Picaut, Anne-Sophie Grandoulier, Jean-Michel Gracies
OBJECTIVE: To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb spasticity previously treated with botulinum toxin A (BoNT-A). DESIGN: A post hoc analysis from a Phase 3, prospective, double-blind, randomized, placebo-controlled study (NCT01313299). SETTING: A total of 34 neurology or rehabilitation clinics in 9 countries. PARTICIPANTS: Adults aged 18-80 years with hemiparesis, ≥6 months after stroke or traumatic brain injury...
June 16, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28623614/abobotulinumtoxina-a-review-in-pediatric-lower-limb-spasticity
#6
Yahiya Y Syed
AbobotulinumtoxinA (Dysport(®)) is currently the only botulinum toxin A formulation approved by the US FDA for the treatment of lower limb spasticity in pediatric patients aged ≥2 years. Intramuscular abobotulinumtoxinA was approved based on the results of a pivotal phase 3 trial in children with lower limb spasticity due to cerebral palsy. In this trial, a single treatment cycle with abobotulinumtoxinA 10-15 U/kg/leg injected into the gastrocnemius and soleus muscles significantly improved ankle plantar flexor muscle tone (primary endpoint), with abobotulinumtoxinA recipients showing a significant response to treatment relative to placebo...
August 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28590525/effects-of-repeated-abobotulinumtoxina-injections-in-upper-limb-spasticity
#7
Jean-Michel Gracies, Michael O'Dell, Michele Vecchio, Peter Hedera, Serdar Kocer, Monika Rudzinska-Bar, Bruce Rubin, Sofiya L Timerbaeva, Anna Lusakowska, François Constant Boyer, Anne-Sophie Grandoulier, Claire Vilain, Philippe Picaut
INTRODUCTION: The efficacy of single injections of abobotulinumtoxinA (Dysport®) is established in adults with upper limb spasticity. This study aimed to assess the effects of repeated injections of abobotulinumtoxinA over 1 year. METHODS: Patients (n=258 safety population) received 500U, 1000U or 1500U (1500U dose included 500U shoulder injections) for up to 4 or 5 treatment cycles. Assessments included treatment-emergent adverse events (TEAEs), muscle tone, passive and active range of motion (XV1, XA ), angle of catch (XV3 ), Disability Assessment Scale (DAS), Modified Frenchay Scale (MFS) and Physician Global Assessment (PGA)...
June 7, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/28465830/economics-of-botulinum-toxin-therapy-influence-of-the-abobotulinumtoxina-package-size-on-the-costs-of-botulinum-toxin-therapy
#8
Dirk Dressler, Fereshte Adib Saberi
BACKGROUND: AbobotulinumtoxinA (Dysport®) was distributed for many years in vials containing 500MU (D500). Recently a new 300MU vial (D300) was additionally introduced (introduction). We wanted to explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic. METHODS: The study followed a retrospective chart review design based on our digital BT therapy data bank. All patients receiving Dysport® exclusively in a constant dose during the observation period (introduction ± 7 months) were included...
2017: Journal of Clinical Movement Disorders
https://www.readbyqxmd.com/read/28458568/cost-effectiveness-analysis-of-abobotulinumtoxina-for-the-treatment-of-cervical-dystonia-in-the-united-kingdom
#9
Madhusubramanian Muthukumar, Kamal Desai, Seye Abogunrin, Timothy Harrower, Sylvie Gabriel, Jerome Dinet
BACKGROUND: Cervical dystonia (CD) involves painful involuntary contraction of the neck and shoulder muscles and abnormal posture in middle-aged adults. Botulinum neurotoxin type A (BoNT-A) is effective in treating CD but little is known about its associated cost-effectiveness. OBJECTIVE: To evaluate the cost-effectiveness of abobotulinumtoxinA for treating CD from the UK payer perspective. METHODS: A Markov model was developed to evaluate the cost-effectiveness of abobotulinum-toxinA versus best supportive care (BSC) in CD, with a lifetime horizon and health states for response, nonresponse, secondary nonresponse, and BSC in patients with CD (mean age: 53 years; 37% male)...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28431634/multicenter-observational-study-of-abobotulinumtoxina-neurotoxin-in-cervical-dystonia-the-anchor-cd-registry
#10
Richard M Trosch, Alberto J Espay, Daniel Truong, Ramon Gil, Carlos Singer, Peter A LeWitt, Mark F Lew, Michele Tagliati, Charles H Adler, Jack J Chen, Dominic Marchese, Cynthia L Comella
BACKGROUND: The ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice. METHODS: Adults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction≥25% and Patient Global Impression of Change [PGIC] score of +2 or +3 at Week 4 of Cycle 1)...
May 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28388721/safety-and-patient-satisfaction-of-abobotulinumtoxina-for-aesthetic-use-a-systematic-review
#11
REVIEW
Joel L Cohen, Nicolo Scuderi
A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted. In addition to the licensed indications, other special populations were considered for discussion. The potential impact of neutralizing antibodies and systemic toxicity were also addressed. A total of 364 papers were screened and 86 were found to be relevant to the population, intervention(s), and outcomes stipulated in the protocol...
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28388720/new-uses-of-abobotulinumtoxina-in-aesthetics
#12
REVIEW
Joel Schlessinger, Erin Gilbert, Joel L Cohen, Joely Kaufman
BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance...
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28388719/the-practical-use-of-abobotulinumtoxina-in-aesthetics
#13
REVIEW
Michael A C Kane, Gary Monheit
Botulinum toxin (BoNT) has been approved for aesthetic use since 2002. Since then, clinical studies and expert use have informed our understanding of how BoNT exerts its clinical effect and the practical use of this product across a number of aesthetic applications. This review discusses the clinical properties and characteristics of abobotulinumtoxinA, which patients are suitable for its use, and how it can be utilized to treat facial rhytides.
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28388718/abobotulinumtoxina-a-25-year-history
#14
REVIEW
Gary D Monheit, Andy Pickett
During the late 1960s and early 1970s, Alan Scott showed that intramuscular injections of botulinum toxin (BoNT) corrected nonaccommodative strabismus without resorting to surgery. The UK doctors who trained with Scott soon realized the significant potential offered by BoNT type A as a therapeutic option for several difficult-to-treat diseases. This led to a collaboration between these pioneering clinicians and the Centre for Applied Microbiology and Research at Porton Down, United Kingdom, and, in turn, to the development and commercialization of abobotulinumtoxinA as Dysport (Dystonia/Porton Down; Ipsen Biopharm Ltd...
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28388717/key-parameters-for-the-use-of-abobotulinumtoxina-in-aesthetics-onset-and-duration
#15
REVIEW
Mark Nestor, Glynis Ablon, Andy Pickett
Time to onset of response and duration of response are key measures of botulinum toxin efficacy that have a considerable influence on patient satisfaction with aesthetic treatment. However, there is no overall accepted definition of efficacy for aesthetic uses of botulinumtoxinA (BoNT-A). Mechanical methods of assessment do not lend themselves to clinical practice and clinicians rely instead on assessment scales such as the Frontalis Activity Measurement Standard, Frontalis Rating Scale, Wrinkle Severity Scale, and Subject Global Assessment Scale, but not all of these have been fully validated...
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28388716/introduction-to-the-supplement-a-review-of-abobotulinumtoxina-dysport
#16
Jeffrey S Dover
No abstract text is available yet for this article.
May 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28375973/incobotulinumtoxina-for-aesthetic-indications-a-systematic-review-of-prospective-comparative-trials
#17
REVIEW
Welf Prager, Diana Nogueira Teixeira, Phillip S Leventhal
BACKGROUND: IncobotulinumtoxinA is a botulinum toxin type A (BoNTA) indicated for temporary improvement in the appearance of upper facial lines with well-established efficacy and safety profiles. Whether incobotulinumtoxinA and other BoNTAs are equipotent is subject of debate. OBJECTIVE: To compare the efficacy of incobotulinumtoxinA and other BoNTAs for aesthetic applications. MATERIALS AND METHODS: PubMed and Embase were systematically searched for prospective clinical trials comparing incobotulinumtoxinA with onabotulinumtoxinA, abobotulinumtoxinA, or placebo for aesthetic applications...
July 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28367260/a-single-blind-split-face-randomized-pilot-study-comparing-the-effects-of-intradermal-and-intramuscular-injection-of-two-commercially-available-botulinum-toxin-a-formulas-to-reduce-signs-of-facial-aging
#18
Priya Sapra, Shantel Demay, Sheetal Sapra, Julie Khanna, Kelli Mraud, Jennifer Bonadonna
Objective: To examine the effectiveness of intradermal botulinum toxin type A injection in improving skin texture and midface lift while reducing pore size and sebum production, as well as investigate the differences in effectiveness between onabotulinumtoxinA and abobotulinumtoxinA using intradermal and intramuscular injection methods. Design: A 16-week, single-blind, split-face, randomized study. Each patient served as their own control, receiving onabotulinumtoxinA and abobotulinumtoxinA randomized to either the left or right side of the face...
February 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/28263010/bilateral-analgesic-effects-of-abobotulinumtoxina-dysport-%C3%A2-following-unilateral-administration-in-the-rat
#19
C Favre-Guilmard, P-E Chabrier, M Kalinichev
BACKGROUND: In addition to inhibition of muscle and glandular hyperactivity, botulinum neurotoxin (BoNT) type A also interferes with pain processing. Previously, in a rat model of paclitaxel-induced polyneuropathy, abobotulinumtoxinA (aboBoNT-A) elicited analgesic effects not only in the injected paw, but also in the contralateral, non-injected paw. METHODS: Here, we assessed bilateral analgesic effects of unilateral aboBoNT-A in several chronic pain models in Sprague-Dawley rats...
May 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/28200002/liquid-formulation-of-abobotulinumtoxina-exhibits-a-favorable-efficacy-and-safety-profile-in-moderate-to-severe-glabellar-lines-a-randomized-double-blind-placebo-and-active-comparator-controlled-trial
#20
Benjamin Ascher, Philippe Kestemont, Dominique Boineau, Isaac Bodokh, Annette Stein, Marc Heckmann, Markus Dendorfer, Tatjana Pavicic, Magali Volteau, Anissa Tse, Philippe Picaut, Berthold Rzany
No abstract text is available yet for this article.
February 14, 2017: Aesthetic Surgery Journal
keyword
keyword
9458
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"